Aaron Lisberg is an Oncology physician affiliated with APLA Health. OpenAlex indexes 200 publications with 10,003 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2020 Santa Monica Blvd Ste 600
Santa Monica, CA 904042131
Telephone
310-826-5471Registry record last updated 21 Aug 2019.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BioNTech SEProgram year20254 payments$19,749openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202510 payments$11,239openpaymentsdata.cms.gov ↗
- Aadi Bioscience, Inc.Program year20253 payments$10,800openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.8%Kinase inhibitor67.8%Tagrisso100%Part D<11 patientsSensory organs
32.2%Corticosteroid32.2%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
University of California Los Angeles
FY2026$540,734R01CA292866 - Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
University of California Los Angeles
FY2025$531,379R01CA292866 - Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
University of California Los Angeles
FY2024$257,099K08CA245249
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Journal of Thoracic Oncology
2025 - OA10.01 Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01
Journal of Thoracic Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Sven De Vos, MD
APLA Health
Ronald Mitsuyasu, MD
APLA Health
Steven Mittelman, MD
APLA Health
Brigitte Gomperts, MD
APLA Health
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”